Therapy of paraneoplastic disorders of the CNS

Simple item page
dc.contributor.authorPaul, N.
dc.contributor.authorKleinig, T.
dc.date.issued2014
dc.description.abstractParaneoplastic neurological syndromes affecting the CNS are rare, presenting in less than 1% of all those with cancer. However, they account for significant disability and may respond to treatment. The pathogenesis of paraneoplastic neurological syndromes is presumed to relate to loss of self-tolerance spilling over from the immune attack on the underlying neoplasm. Testing for anti-neuronal antibodies is now available in most tertiary laboratories, enabling targeted therapies. While the evidence base for treatment is limited, the response to treatment can be largely determined based on the location of the target antigen; antibodies against cell surface antigens responding well to treatments targeting the humoral response. Intracellular antigen-target syndromes respond less well, but may theoretically respond best to T-cell based therapies. In both cases, aggressive tumor therapy is indicated.
dc.description.statementofresponsibilityNicola Lisa Marie Paul and Timothy John Kleinig
dc.identifier.citationExpert Review of Neurotherapeutics, 2014; 15(2):187-193
dc.identifier.doi10.1586/14737175.2015.1000310
dc.identifier.issn1473-7175
dc.identifier.issn1744-8360
dc.identifier.orcidKleinig, T. [0000-0003-4430-3276]
dc.identifier.urihttp://hdl.handle.net/2440/99984
dc.language.isoen
dc.publisherTaylor & Francis
dc.rights© 2015 Informa UK Ltd
dc.source.urihttps://doi.org/10.1586/14737175.2015.1000310
dc.subjectCentral Nervous System
dc.subjectAnimals
dc.subjectHumans
dc.subjectNeoplasms
dc.subjectNerve Tissue Proteins
dc.subjectAutoantibodies
dc.subjectAntigens, Neoplasm
dc.subjectImmunotherapy
dc.titleTherapy of paraneoplastic disorders of the CNS
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Medicine publications